Three things investors will be looking for in Biogen's Q3 earnings

The drugmaker will again face analysts on Tuesday amid cautious hope for its neurodegenerative disease drugs and an ongoing CEO search. Here's what to watch for.

Three things investors will be looking for in Biogen's Q3 earnings
The drugmaker will again face analysts on Tuesday amid cautious hope for its neurodegenerative disease drugs and an ongoing CEO search. Here's what to watch for.